Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 10/20 | 0.47 |
| ▸ | TACR3 | P29371 | 14/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | DHODH | Q02127 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5908752 | 0.94 | TACR2 (0.48) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5448850 | 0.90 | TACR3 (0.49) | TACR2TACR3KCNH2OPRM1 | |
| SCHEMBL5442117 | 0.90 | TACR3 (0.47) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5908771 | 0.89 | TACR3 (0.50) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5438840 | 0.89 | TACR2 (0.48) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5423565 | 0.89 | DHODH (0.52) | PDE10ADHODH | |
| SCHEMBL5418589 | 0.89 | TACR2 (0.47) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL5427501 | 0.88 | KDM4E (0.40) | TACR2TACR3KCNH2OPRM1LMNA | |
| SCHEMBL5451916 | 0.88 | TACR3 (0.49) | TACR2TACR3KCNH2OPRM1PDE10A | |
| SCHEMBL6361371 | 0.88 | TACR3 (0.51) | TACR2TACR3KCNH2OPRM1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. | 2007-11-08 | — | — | US | disclosed |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | GLAXOSMITHKLINE S.P.A. (IT) | 2006-10-12 | — | — | US | disclosed |
| EP-1659120-A1 | 3-substituted quinoline-4-carboxamide derivatives as NK-3 and NK-2 receptor antagonists | GlaxoSmithKline S.p.A. (IT) | 2006-05-24 | — | — | EP | disclosed |
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | SMITHKLINE BEECHAM S.P.A. (IT) | 2004-09-16 | — | — | US | disclosed |
| EP-1385839-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GlaxoSmithKline S.p.A. (IT) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002083664-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | GLAXOSMITHKLINE S.P.A. (IT) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180902-A1 | 3-Substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists | HRH4, HRH2, HRH3 | TACR2 6/4885TACR3 60/4885KCNH2 15/4885 |
| US-20070259882-A1 | 3-SUBSTITUTED QUINOLINE-4-CARBOXAMIDE DERIVATIVES AS NK-3 AND NK-2 RECEPTOR ANTAGONISTS | KCNK3, KCNJ2, KCNK2 | TACR2 12/4885TACR3 19/4885KCNH2 16/4885 |
| US-20060229315-A1 | 3-Substituted Quinoline-4-Carboxamide Derivatives as NK-3 and NK-2 Receptor Antagonists | KCNK3, KCNJ2, KCNK2 | TACR2 12/4885TACR3 19/4885KCNH2 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.